in Off topic
Thu Nov 09, 2017 3:09 am
• 1.035 Posts
"We are encouraged by these interim results, and Phase III trials are currently underway," said David Nicholson, Ph.D., Executive Vice President and President, Global Brands Research & Development, Allergan. "Bimatoprost SR has the potential to be a novel approach to treat glaucoma beyond conventional eye drop treatments and illustrates our commitment to bringing innovative solutions for physicians to help them meet the needs of their patients."
In the Phase I/II dose-ranging, paired-eye controlled clinical trial, a total of 75 patients received the implant via an intracameral injection in one eye, and daily topical bimatoprost 0.03% in the other eye. The dose strengths of Bimatoprost SR were 6, 10, 15, or 20 micrograms. All dose strengths of Bimatoprost SR were comparable with topical bimatoprost 0.03% in overall IOP reduction through week 16. The overall mean IOP reduction from baseline at 4 months in study eyes that received a single Bimatoprost SR implant ranged from 7.2 to 9.5 mm Hg while pooled fellow eyes receiving once-daily treatment with topical bimatoprost 0.03% had a reduction of 8.4 mm Hg. At month 6, 71 percent (n=53) of study eyes still had not received topical IOP-lowering rescue or a second injection of Bimatoprost SR.You do not have to rely on those falsies or eyelash extensions.Careprost bimatoprost ophthalmic price is approved by the US Food and Drug Administration, so donít be apprehensive to use bimatoprost. Long and thick eyelashes donít just happen overnight.?And Itís better to use careprost on sale than stopping your natural growth of eyelashes by using fake eyelashes. You will notice eyelash growth after four months of daily use of it.
"Patients having challenges in taking their daily eye drops is one of the greatest challenges we face as eye care physicians," said Richard Lewis, M.D., clinical trial investigator, former director of glaucoma at the University of California, Davis, and ophthalmologist at Sacramento Eye Consultants. "The results seen to date indicate that Bimatoprost SR may offer patients a non-daily treatment option that is administered by a physician."